[Beta blockaders in the treatment of hypertension. Part 2. Antihypertensive effect: hypotheses on the mechanism of action and practical methods of treatment].
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008914:Minoxidil / Q000627:therapeutic use; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D014665:Vasodilator Agents; D010643:Phenoxybenzamine; D006830:Hydralazine; D008914:Minoxidil; D011433:Propranolol
Les bêta-bloquants dans le traitement de l'hypertension artérielle. 2 partie. L'effet antihypertenseur: hypothèses concernant le mécanisme d'action et modalités pratiques du traitement.